唑来膦酸联合阿法骨化醇和钙剂治疗骨质疏松的临床疗效分析

Analysis of clinical efficacy of zoledronic acid combined with alfa-calcidol and calcium tablets in the treatment of osteoporosis

目的分析唑来膦酸联合阿法骨化醇和钙剂治疗骨质疏松的临床疗效。方法收集2015年4月至2018年4月我院收治的102例骨质疏松患者,采用随机数字表法分为对照组(51例,单纯钙剂治疗)和试验组(51例,唑来膦酸+阿法骨化醇+钙剂治疗),从骨密度、VAS评分、生活质量等方面评价疗效。结果治疗后试验组骨密度显著较对照组高,差异有统计学意义(P<0.05);试验组VAS评分显著低于对照组的,差异有统计学意义(P<0.05);试验组生活质量评分显著较对照组高,差异有统计学意义(P<0.05)。结论唑来膦酸联合阿法骨化醇和钙剂可有效提高骨质疏松患者骨密度,缓解疼痛症状,改善生活质量。

Objective To analyze the clinical curative effect of zoledronic acid combined with alfa-calcidol and calcium tablets in the treatment of osteoporosis. Methods From April 2015 to April 2018, 102 patients with osteoporosis in our hospital were recruited, and randomized into the control group(51 cases, simple calcium-tablet therapy) and test group(51 cases, zoledronic acid + alfa-calcidol + calcium tablets) using random digital table method. Bone mineral density, clinical efficacy, VAS score and quality of life were compared between the two groups. Results The BMD of the experimental group at proximal femur, greater trochanter, femoral neck and L1-L4 was all significantly higher than that of the control group, P<0.05. The total clinical efficiency of the experimental group was significantly higher than that of the control group, P<0.05(with statistical difference). VAS score of the experimental group was significantly lower than that of the control group, P<0.05(with statistical difference). The quality of life score of the experimental group was significantly higher than that of the control group, P<0.05(with statistical difference). Conclusion Combined with alfa-calcidol and calcium tablets, zoledronic acid could effectively improve bone density, alleviate pain symptoms and improve quality of life in patients with osteoporosis.